ESR2 and ovarian neoplasm: These findings, combined with the aforementioned clinical correlations between ERβ and patient survival, lead us to hypothesize that ERβ is a critical factor in ovarian tumor progression and to delineate the precise contribution of this receptor in the molecular pathways underlying EOC carcinogenesis.